JPMorgan Chase & Co. Reduces Stock Holdings in Sera Prognostics, Inc. (NASDAQ:SERA)

JPMorgan Chase & Co. reduced its position in Sera Prognostics, Inc. (NASDAQ:SERA) by 12.3% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 775,871 shares of the company’s stock after selling 108,996 shares during the quarter. JPMorgan Chase & Co. owned approximately 2.30% of Sera Prognostics worth $6,316,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently made changes to their positions in the company. Pallas Capital Advisors LLC purchased a new stake in Sera Prognostics in the 4th quarter worth about $113,000. Jane Street Group LLC boosted its position in Sera Prognostics by 24.8% during the third quarter. Jane Street Group LLC now owns 14,225 shares of the company’s stock worth $111,000 after purchasing an additional 2,826 shares during the period. Rhumbline Advisers increased its stake in shares of Sera Prognostics by 10.6% in the fourth quarter. Rhumbline Advisers now owns 36,101 shares of the company’s stock worth $294,000 after purchasing an additional 3,468 shares in the last quarter. Barclays PLC raised its position in shares of Sera Prognostics by 321.6% in the third quarter. Barclays PLC now owns 39,450 shares of the company’s stock valued at $308,000 after purchasing an additional 30,093 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of Sera Prognostics by 5.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 81,228 shares of the company’s stock valued at $661,000 after buying an additional 4,115 shares in the last quarter. 54.64% of the stock is currently owned by institutional investors.

Sera Prognostics Trading Up 1.5 %

SERA opened at $3.40 on Friday. Sera Prognostics, Inc. has a 12 month low of $2.99 and a 12 month high of $12.36. The company has a market cap of $128.06 million, a PE ratio of -3.43 and a beta of 0.96. The company has a 50 day moving average of $3.86 and a 200 day moving average of $5.98.

Sera Prognostics (NASDAQ:SERA) last announced its quarterly earnings results on Wednesday, March 19th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.02). The firm had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.01 million. During the same period in the previous year, the business posted ($0.25) EPS. Research analysts forecast that Sera Prognostics, Inc. will post -0.96 earnings per share for the current fiscal year.

Sera Prognostics Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.